Myla Lai - Jun 1, 2022 Form 4 Insider Report for Akoya Biosciences, Inc. (AKYA)

Role
Director
Signature
Myla Lai-Goldman, by Brian McKelligon, as Attorney-in-Fact
Stock symbol
AKYA
Transactions as of
Jun 1, 2022
Transactions value $
$0
Form type
4
Date filed
6/3/2022, 04:06 PM
Previous filing
May 26, 2022
Next filing
Apr 27, 2023

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction AKYA Stock Option (Right to Buy Award $0 +30.5K $0.00 30.5K Jun 1, 2022 Common Stock 30.5K $11.24 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Subject to the reporting person's continuous service through the vesting date, the options shall vest in full on the earlier of (a) June 1, 2023, or (b) the date of the next annual meeting of Akoya Biosciences, Inc. occurring after the date of grant.